Dynamic light scattering of the eye in the diagnosis of Alzheimer's disease.

The early detection of Alzheimer's disease, before symptoms have appeared, is integral to the development of effective treatments. Dynamic light scattering spectroscopy measures the Brownian movement of proteins at the molecular level. This technique may facilitate early Alzheimer's disease diagnosis and the discovery of pharmaceuticals that may prevent symptom development.

Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Stargardt Disease.

Stargardt Disease is the most common inherited macular degeneration, typically resulting in progressive central vision loss and legal blindness at an early age. We report regarding 34 eyes with Stargardt Disease treated in the Stem Cell Ophthalmology Treatment Study (SCOTS and SCOTS2). Autologous bone marrow was processed, separating the stem cell fraction which was provided Arms using retrobulbar, subtenons, intravitreal or subretinal and intravenous.

Stem Cell Ophthalmology Treatment Study (SCOTS): Bone Marrow-Derived Stem Cells in the Treatment of Age-Related Macular Degeneration.

Dry age-related macular degeneration (AMD) is one of the leading causes of vision loss in older patients. The macula accumulates drusen with loss of retinal pigment epithelial cells and photoreceptors. Abnormal subretinal neovascularization is absent.

Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow derived stem cells in the treatment of Dominant Optic Atrophy.

Background: We report the results of 6 patients with Dominant Optic Atrophy (DOA) who met inclusion criteria and were treated in the Stem Cell Ophthalmology Treatment Study (SCOTS). SCOTS/SCOTS 2 is an Institutional Review Board approved and NIH registered (NCT03011541) clinical study that uses autologous bone marrow derived stem cells (BMSC) in the treatment of optic nerve and retinal disease.

Methods: This is an open label, non-randomized clinical study using natural history of the disease as the comparator.

Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow derived stem cells in the treatment of Usher syndrome.

Background: Usher syndrome is the most common form of syndromic retinitis pigmentosa and includes types I, II, and III with varying degrees of hearing loss. We present results of 10 eyes with Usher syndrome treated with autologous bone marrow derived stem cells (BMSC) within the Stem Cell Ophthalmology Treatment Study (SCOTS).

Methods: Preoperative Snellen visual acuities ranged from 20/30-1 to 20/400 with the average pre-operative Snellen acuity approximately 20/85 and the average logarithm of the minimum angle of resolution (LogMAR) acuity 0.

Dynamic light scattering spectroscopy of the retina-a non-invasive quantitative technique to objectively document visual improvement following ocular stem cell treatment.

Background: A major difficulty in retinal research is the lack of a sensitive and quantitative method to objectively determine the functional ability of the retina. Dynamic light scattering (DLS) spectroscopy is a non-invasive quantitative technique that measures the thermal random motion of particles. DLS technology has been used to predict cataractogenesis in rabbits and detect and monitor diabetes mellitus in humans.

Stem Cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of Retinitis Pigmentosa.

Background: Seventeen patients with bilateral visual loss due to Retinitis Pigmentosa (RP) underwent autologous bone marrow derived stem cell (BMSC) treatment within the Stem Cell Ophthalmology Treatment Study (SCOTS and SCOTS 2). Both are National Institutes of Health (NIH) and Office of Human Research Protection (OHRP) compliant Institutional Review Board (IRB) approved clinical studies utilizing using autologous BMSC in the treatment of retinal and optic nerve diseases that meet inclusion criteria.

Methods: The average age of the patients treated was 48.

Stem Cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of non-arteritic ischemic optic neuropathy (NAION).

Background: Ten patients with bilateral visual loss due to sequential non-arteritic ischemic optic neuropathy (NAION) underwent autologous Bone Marrow Derived Stem Cell (BMSC) therapy within the Stem Cell Ophthalmology Treatment Study (SCOTS). SCOTS is an Institutional Review Board approved clinical study utilizing autologous BMSC in the treatment of optic nerve and retinal diseases that meet inclusion criteria.

Methods: The average age of the patients treated was 69.

Stem Cell Ophthalmology Treatment Study (SCOTS): bone marrow-derived stem cells in the treatment of Leber's hereditary optic neuropathy.

The Stem Cell Ophthalmology Treatment Study (SCOTS) is currently the largest-scale stem cell ophthalmology trial registered at ClinicalTrials.gov (identifier: NCT01920867). SCOTS utilizes autologous bone marrow-derived stem cells (BMSCs) to treat optic nerve and retinal diseases.

Stem Cell Ophthalmology Treatment Study (SCOTS): improvement in serpiginous choroidopathy following autologous bone marrow derived stem cell treatment.

We report results in a 77-year-old male patient with visual loss from long-standing serpiginous choroidopathy treated with bone marrow derived stem cells (BMSC) within the Stem Cell Ophthalmology Treatment Study (SCOTS). SCOTS is an Institutional Review Board approved clinical trial and the largest ophthalmology stem cell study registered at the National Institutes of Health to date (ClinicalTrials.gov Identifier: NCT01920867).

Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a case report of improvement in relapsing auto-immune optic neuropathy.

We present the results from a patient with relapsing optic neuropathy treated within the Stem Cell Ophthalmology Treatment Study (SCOTS). SCOTS is an Institutional Review Board approved clinical trial and has become the largest ophthalmology stem cell study registered at the National Institutes of Health to date (www.clinicaltrials.

Stem Cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a preliminary report.

In this report, we present the results of a single patient with optic neuropathy treated within the Stem Cell Ophthalmology Treatment Study (SCOTS). SCOTS is an Institutional Review Board approved clinical trial and is the largest ophthalmology stem cell study registered at the National Institutes of Health to date- www.clinicaltrials.

Hyperbaric oxygen treatment of retinal artery occlusion.

Five patients with a one- to 12-day history of symptoms secondary to retinal artery occlusion (RAO) were treated with hyperbaric oxygen therapy (HBO2) for one hour at 1.5 ATA. Four patients had been diagnosed with branch retinal artery occlusion (BRAO) and one patient with a cilioretinal artery occlusion.

Hyperbaric oxygen therapy and age-related macular degeneration.

Age-related macular degeneration (AMD) is a significant cause of visual loss in the United States and Western Europe. As the population ages, the prevalence rate of advanced AMD is expected to double by 2030. A one-hour session of hyperbaric oxygen therapy (HBO2) was used to treated a group of 14 patients with advanced AMD.

Hyperbaric oxygen treatment of nonacute central retinal artery occlusion.

Four patients received hyperbaric oxygen therapy (HBOT): Three patients had nonarteritic central retinal artery occlusion (CRAO); a fourth patient had a CRAO in the right eye (OD) and a branch retinal artery occlusion (BRAO) with macular involvement in the left eye (OS) secondary to giant cell arteritis. The first two patients presented with a one-day history of CRAO, the third patient with a 10-day history of CRAO OD and the fourth patient with a three-week history of CRAO OD and a three-day history of BRAO OS. The initial visual acuities ranged from light perception to counting fingers at 6 feet.

Retinal endovascular surgery and intravitreal triamcinolone acetonide for central vein occlusion in young adults.

Purpose: To report the results of retinal endovascular surgery and intravitreal triamcinolone acetonide on two eyes of two patients younger than 40 years of age with central vein occlusion.

Design: Interventional case reports from a study approved by the Institutional Review Board of North Broward Medical Center, Pompano Beach, Florida.

Methods: Two men, ages 37 and 39, with unilateral central vein occlusion were treated with retinal endovascular surgery and intravitreal triamcinolone acetonide.